{xtd_wp_head}
Skip to content
About
Technology
Innovators
Students
Industry
Available Technology

Biomedical

Fusogenic Peptides for Delivery of RNAi Therapeutics to Ovarian Cancer

Inventors: Angela Alexander-Bryant, Timothy Samec

Market Overview

The novel fusogenic peptides improve the delivery of therapeutics for ovarian cancer through their ability to enhance endosomal escape and delivery of bioactive therapeutics. Epithelial ovarian cancer is the 5th leading cancer among women, with a 49% five-year survival rate. Current treatment strategies for ovarian cancer include surgical removal, chemotherapy, and radiation; however, these treatments often prove ineffective or toxic to patients. Global News Wire expects the nanotechnology drug delivery market to have an 18.7% CAGR growth rate from 2022 to 2032. Current chemotherapies are limited due to the toxicity of therapeutic and resistance to treatment. Furthermore, there has been increased attention to reducing systemic effects and therapeutic concentration. This technology fills this gap by providing a means of delivery for therapeutics of RNA interference (RNAi), a mechanism used to silence genes responsible for cancer prognosis. While a
promising strategy for treatment, RNAi cargo needs a delivery system to improve its bioavailability
and delivery into cancer cells. Clemson University researchers have developed novel fusogenic
peptides that have efficient delivery into ovarian cancer cells and enable the endosomal escape of
therapeutic.

Applications:

The fusogenic peptides are a delivery system designed to improve the intracellular delivery and endosomal escape of RNAi cargo to improve gene silencing for cancer treatment.

Technical Summary:

The peptides' design is composed of alternating residues of hydrophobic and hydrophilic amino acids, highlighted by repeating aspartic acid residues. Due to the inclusion of a cationic tail, these peptides have shown effective electrostatic complexation and protection of RNAi cargo. High biocompatibility and cellular internalization have been shown both in vitro and in vivo. These sequences have proven to enhance endosomal escape through the protonation of hydrophobic amino acids, which leads to a conformational change in a more acidic pH to disrupt the endosomal
membrane. Upon release from the endosome, the siRNA is released into the cytoplasm of the cell, where it can be bioactive. Due to this enhanced delivery, gene silencing studies showed the system's efficacy in silencing the target oncogene. Therefore, these novel peptides demonstrate a highly efficient delivery system for RNAi therapeutic applications for cancer treatment.

Advantages:

  • Facilitates endosomal release of cargo, increasing the bioavailability of therapeutic 
  • Electrostatic complexation of cargo, resulting in a wide range of potential cargo 
  • High biocompatibility and tumor localization, lowering adverse systemic effects compared to current treatments

Download Printable PDF

Technology Overview

State of Development

TR:2

Patent Type

Provisional

Category

Biomedical

Serial Number

63/303,670

CURF Reference No.

2021-025

Inventors

Angela Alexander-Bryant, Timothy Samec

Get Started
Ready to Get Started?

Contact our team at CURF

Contact CURF